- Home
- RNXT
RNXT
RenovoRx Inc.
as of 04-07-2026 11:10am EST
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 37.0M | IPO Year: | 2021 |
| Target Price: | $8.00 | AVG Volume (30 days): | 456.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.32 | EPS Growth: | 20.00 |
| 52 Week Low/High: | $0.70 - $1.45 | Next Earning Date: | 05-14-2026 |
| Revenue: | $1,123,000 | Revenue Growth: | 2511.63% |
| Revenue Growth (this year): | 267.59% | Revenue Growth (next year): | 307.07% |
| P/E Ratio: | -2.91 | Index: | N/A |
| Free Cash Flow: | -10975000.0 | FCF Growth: | N/A |
AI-Powered RNXT Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of RenovoRx Inc. (RNXT)
Chief Executive Officer
Avg Cost/Share
$0.00
Shares
24,300
Total Value
$0.00
Owned After
313,357
SEC Form 4
Director
Avg Cost/Share
$0.00
Shares
9,720
Total Value
$0.00
Owned After
9,720
SEC Form 4
Chief Medical Officer
Avg Cost/Share
$1.00
Shares
10,000
Total Value
$9,975.00
Owned After
798,460
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Bagai Shaun | RNXT | Chief Executive Officer | Mar 20, 2026 | Buy | $0.00 | 24,300 | $0.00 | 313,357 | |
| Marton Laurence | RNXT | Director | Mar 20, 2026 | Buy | $0.00 | 9,720 | $0.00 | 9,720 | |
| VOLL MARK | RNXT | Chief Financial Officer | Mar 20, 2026 | Buy | $0.00 | 97,200 | $0.00 | 97,200 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Jan 21, 2026 | Buy | $1.00 | 10,000 | $9,975.00 | 798,460 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 13, 2025 · 100% conf.
Q3 2025 Earnings
8-K SELLNov 13, 2025 · 100% conf.
1D
-3.50%
$0.94
Act: -23.03%
5D
-14.82%
$0.83
Act: -20.11%
20D
-5.84%
$0.92
Act: -1.48%
Transcript text not available. View on SEC.gov →
2025 Q2 Q2 2025 Earnings
8-K Aug 14, 2025
Q2 2025 Earnings
8-KAug 14, 2025
2025 Q1 Q1 2025 Earnings
8-K May 15, 2025
Q1 2025 Earnings
8-KMay 15, 2025
Compare RNXT vs Leading Stocks
See how RNXT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.